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Abstract
Objectives—To present a rationale and a proposed structure to support pharmacist-delivered 
medication therapy management (MTM) for human immunodeficiency virus (HIV) disease and to 
outline challenges to implementing and sustaining the service.
Data sources—Professional literature.
Summary—Historically, the effect of pharmacy services for HIV-infected persons has been 
demonstrated in inpatient and clinic-based settings. Developing similar programs adapted for 
community pharmacists could be a model of care to improve patient adherence to antiretroviral 
therapy and retention in care. Initiation of antiretroviral therapy and regular monitoring of CD4+ 
cell count, HIV RNA viral load, adverse drug events, and adherence form the backbone of 
successful medical management of HIV infection. Support for these services can be provided to 
HIV-infected patients through pharmacist-managed HIV MTM programs in community pharmacy 
settings in collaboration with primary providers and other health care professionals.
Conclusion—Community pharmacists can help meet the growing need for HIV care through 
provision of MTM services. Although resources have been developed, including the general MTM 
framework, challenges of adequate training, education, and support of community pharmacists 
need to be addressed in order for HIV MTM to be a successful model.
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In the 21st century, care of persons infected with human immunodeficiency virus (HIV) has 
transitioned from treatment of an acute illness to comprehensive management of a chronic 
infection accompanied by a number of comorbidities.1 HIV-infected patients are typically 
referred to infectious disease specialists, a model of care that meets patients’ needs. As more 
effective therapy has led to profound reductions in HIV-associated morbidity and mortality, 
providers are faced with the challenges of long-term management of HIV infection and other 
comorbidities.2 Adverse effects associated with antiretroviral therapy (ART), continued 
inflammation despite virologic control, and increased risk of age-associated nonAIDS-
related morbidity and mortality become increasingly common clinical problems.2 The 
increasing numbers of persons living with HIV infection requires more primary care 
providers at a time when the HIV health care workforce may be declining.3 A survey of 
American Academy of HIV Medicine members revealed that 45% of the workforce is older 
than 50 years of age and is expected to retire within 10 years, raising concern as to whether 
an adequate workforce committed to care of persons with HIV disease will be available in 
the future.4
In 2010, the White House released the U.S. National HIV/AIDS Strategy emphasizing three 
primary goals: (1) reduce the number of people who become infected with HIV, (2) increase 
access to care and optimize health outcomes for people living with HIV infection, and (3) 
reduce HIV-related health disparities.5 Achieving these goals requires the health care system 
to identify HIV-infected persons at an earlier stage of infection, link infected persons to 
health care practitioners, retain patients in the care system, and provide ART when 
appropriate. The U.S. National HIV/AIDS Strategy suggests increasing the number and 
diversity of health care practitioners to strengthen the current provider workforce and to 
ensure quality HIV care. Pharmacists perform HIV prevention services through syringe 
access programs where allowed by law6 and more recently pharmacies have been used as 
sites to perform rapid HIV testing to identify new HIV-infected persons and refer them to 
care.7–9 Pharmacists are positioned to further fill the workforce gap through provision of 
MTM services to persons with HIV disease by ensuring quality care to improve adherence 
to ART and retention in HIV care. A rationale and proposed structure to support pharmacist-
delivered MTM for HIV disease is presented here, as well as an outline of challenges to 
implementing and sustaining the service.
Rationale for community pharmacist–based medication therapy 
management for HIV
Community pharmacies provide easily accessed locations. A 2007 evaluation of Medicare 
Part D recipients indicated that 90% of urban beneficiaries lived within four miles, and 70% 
of rural beneficiaries lived within 15 miles of a pharmacy.10 Community pharmacists also 
have demonstrated success in managing medication-related needs of patients with chronic 
illness, leading to improvements in clinical outcomes and decreases in health care 
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expenditures.11–14 Furthermore, community pharmacists provide flexible hours for patients 
(e.g., during evenings and weekends). This flexibility provides a way for patients to access 
care at a time and place that may be convenient for them. Lack of flexibility of HIV clinic 
hours to accommodate work schedules has been identified as a barrier to consistent HIV 
care.15 In urban areas, busy or overcrowded clinics may have limited resources for 
comprehensive adherence and retention services. In rural settings, patients often travel long 
distances to receive HIV care, which can deter adherence and retention efforts.16
Supporting literature
Historically, the effect of pharmacist services for persons with HIV infection has been 
documented in clinic-based settings, particularly in promoting antiretroviral adherence.17,18 
An analysis of more than 10,000 new ART-regimen starts in a large, integrated health care 
system demonstrated the value of a clinical pharmacist as a member of a multidisciplinary 
HIV care team, resulting in improvements in ART adherence and CD4+ cell count 
responses.19 Developing similar programs adapted for community pharmacists could 
improve patient adherence to ART and retention in care. These changes will likely improve 
outcome and potentially limit emergence of ART resistance. Specialized MTM programs for 
HIV-infected patients have emerged in response to growing ART-related expenses and to 
improve HIV patient health outcomes. Such a program has been developed by Ramsell 
Pharmacy Solutions and MIRIXA Corp.20
A brief PubMed literature search returned 20 distinct publications using the combined 
search terms “pharmacist medication therapy management and HIV” and “pharmacist 
medication therapy management and antiretroviral.” Five of these articles described 
community-based pharmacist-provided MTM.21–25 Three community-based articles were 
related to the California HIV/AIDS specialty pharmacies selected to provide MTM services 
to HIV/AIDS Medi-Cal patients.21 That study compared medical claims of HIV-infected 
patients in pilot pharmacies offering HIV MTM services with medical claims of HIV-
infected patients in other Medi-Cal pharmacies that did not offer MTM services. 
Investigators observed improved medication adherence for HIV-infected patients who 
received MTM services. An additional 3-year examination of the Medi-Cal HIV MTM 
services demonstrated that pilot pharmacy patients, in comparison to nonpilot pharmacy 
patients, were more likely to have clinically appropriate ART regimens and to be more 
adherent to those regimens.22 This study also demonstrated sustainability of HIV MTM 
services by maintaining satisfactory medication adherence over three years. Provision of 
HIV MTM services resulted in greater drug-related expenditures than expected but was 
associated with lower costs for hospital admissions and emergency room visits. Increased 
expenditures were mostly attributed to nonART medications used to mitigate HIV and ART-
related peripheral neuropathy, gastrointestinal, and psychotherapeutic adverse effects. This 
program indicates both the effect of pharmacists’ HIV MTM services and the potential 
sustainability of HIV MTM services by lowering overall costs associated with patient care.
An additional article compared pharmacies that offer specialized services for HIV-infected 
patients with nonspecialized pharmacies.24 The study demonstrated improvements in 
adherence as measured by proportion of days covered by antiretroviral drug prescriptions as 
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well as persistence with remaining on antiretroviral therapy, though the absolute differences 
were modest.
Another evaluation of patients who filled antiretroviral prescriptions in 2007–09 found that 
those served at any one of seven HIV-specialty Walgreen pharmacies in California had 
better regimen refill adherence as measured by a modified medication possession ratio 
(90%) compared with traditional Walgreens pharmacies in California (77%). The specific 
interventions associated with improvement was not documented, though pharmacists at 
these stores all had completed an HIV certificate training program designed for community 
pharmacists.25
Retention in care, adherence to antiretroviral therapy, and viral suppression should be the 
measures of improvements investigated in future community pharmacy–based MTM 
programs for persons with HIV.
Initiating community pharmacist–based HIV MTM
A first step to achieving HIV MTM programs is for community pharmacists to establish 
formal relationships with health care providers and patients with HIV. Identification and 
communication of key issues to be considered when establishing and formalizing HIV MTM 
services and roles is important. Issues include (1) care coordination, (2) pharmacist 
education and use of available resources, and (3) achievement of reimbursement for 
services.
Care coordination
Care coordination with collaborative relationships (e.g., collaborative practice agreements) 
with primary providers of care can define pharmacists’ role on the interprofessional HIV 
care team. Pharmacists can perform comprehensive HIV MTM to ensure appropriate dose, 
efficacy, safety, and adherence to medications and provide regular reports to providers. 
Access to medical information and the therapeutic goals established in the clinic through an 
electronic medical record would assist pharmacists in doing this. Relationships between 
community pharmacists and other health care providers could be established through 
partnerships between pharmacy networks and HIV clinics. Community pharmacists willing 
to provide MTM services to HIV-infected patients should be identified and connected to 
interested clinics and ultimately linked to patients living with HIV infection in regions.
Care coordination between the community pharmacist and the clinical provider may vary 
depending on the level of HIV expertise of the provider and their clinic staff. The 
community pharmacist’s services may be valuable to a primary care physician who manages 
a few HIV-infected clients without dedicated HIV specialty trained staff. Another instance 
may be a clinic situation where HIV disease is one of many medical conditions the staff 
manages, and where care may be provided by health care professionals without specific 
expertise in HIV medicine, such as primary care physicians, mental health providers, nurse 
practitioners, physician assistants, nurses, and social work staff. A typical example may be a 
federally qualified health center in an underserved area or a place where the pharmacist 
works as a member of a medical home model of care and provides patient education and 
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counseling. Community pharmacists could also provide service to HIV specialty clinics that 
may have HIV expert pharmacists on staff.
In any of these three scenarios, community pharmacists may facilitate regular contact with 
patients between clinic visits to reinforce therapeutic goals and monitor/enhance retention in 
care of patients, preventing loss to follow-up. Pharmacists could be involved in care 
coordination by ensuring patients complete laboratory tests (e.g., CD4+ cell counts, HIV 
RNA viral load, and lab tests to monitor for adverse effects of the drugs) ordered by the 
physician or ordered by the pharmacist under a collaborative practice agreement. Refill 
patterns, adherence to medication, patient tolerability of the regimen, and laboratory results 
could be reviewed and communicated to the physician during regularly scheduled meetings, 
with more rapid feedback for predefined critical lapses in adherence or laboratory values.
Formal relationship establishment and communication of potential roles in care coordination 
and management to patients also may be beneficial. Emphasis of pharmacists’ accessibility 
to patients’ residences (e.g., may be closer and more available to the patient than clinics) can 
create opportunities to establish patient relationships whereby pharmacists play active roles 
in comanaging patients’ care with the primary provider. Patients benefit from the 
convenience of the service location. Additionally, frequent contacts between pharmacists 
and patients for refilling medications can formalize relationship roles in monitoring 
engagement in care and identifying potential nonadherence to medication between 
scheduled clinic visits. Pharmacists can aid in the identification of drug interactions and 
perform medication reconciliation for patients with multiple medical providers.26 Additional 
pharmacists’ roles outside of typical clinic encounters can improve patients’ health literacy 
and improved understanding of medical care through motivational interviewing.27 
Pharmacists’ ability to improve retention in care and adherence can be documented as one 
measure to justify the service.28
Pharmacist HIV education and available resources
To support roles of community pharmacists in HIV MTM, adequate training and mentors 
with expertise in HIV therapy management are required.29 Training in HIV care specifically 
for pharmacists as certificate programs and continuing education programs may be 
appropriate for community pharmacists.30 Training programs targeting a variety of HIV 
providers, including physicians, physician assistants, nurse practitioners, nurses, and 
pharmacists through the AIDS Education & Training Center, may be completed.31 
Pharmacists may obtain credentialing through the American Academy of HIV Medicine.32 
While full credentialing may not be feasible for all community pharmacists, a mentor–
mentee relationship with a pharmacist credentialed in HIV may be a potential strategy to 
ensure expertise in HIV pharmacotherapy. Objectives of these programs typically are to 
train community pharmacists to educate patients about HIV disease and opportunistic 
infections, to promote ART adherence, and to prevent medication-related adverse effects 
and serious drug interactions, with the ultimate goal to improve patient care and decrease 
medication and hospitalization-related expenses.
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Financial sustainability is necessary for effective HIV care delivery, and lack of adequate 
reimbursement for HIV MTM services or for providing medication counseling services has 
been cited as a barrier to provision of optimal MTM services.23,33,34 Adequate 
reimbursement is essential to sustain new MTM services for HIV disease. The value of these 
services will need to be clearly demonstrated to secure payers’ support.35,36 Other changes 
in health care are encouraging as patient-centered medical homes and accountable care 
organizations may represent models of care that could provide a sustainable mechanism for 
reimbursement of pharmacist services in the future.37
Conclusion
HIV management has evolved to the point that HIV MTM can enhance patients’ quality of 
life and decrease mortality. Initiation of ART and regular monitoring of laboratory values, 
adverse drug events, and adherence form the backbone of successful medical management 
of HIV infection. Support for these services can be provided to HIV-infected patients 
through pharmacist-managed HIV MTM programs in community pharmacy settings in 
collaboration with primary providers and systems. Although resources have been developed 
including the general MTM framework, challenges of adequate training, education, and 
support of community pharmacists need to be addressed in order for HIV MTM to be 
successful. With an estimated HIV incidence of nearly 50,000 new cases per year in the 
United States, the need for clinical care for HIV disease continues to grow.38 Community 
pharmacists can help meet this growing need by providing MTM services for HIV-infected 
persons.
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Based on the model of medication therapy management (MTM) focused on specific 
conditions, such as diabetes management, the authors call for the application of MTM in 
HIV/AIDS care. Phamacist-based management of HIV infection has been shown 
effective in speciality clinics, with attention to adherence and monitoring of HIV markers 
such as CD4+ cell count. The authors here advocate extending this management into 
community pharmacies in collaboration with physicians and other health care workers. 
Community-pharmacy HIV MTM would help to fill a gap in accessibility for many 
patients.
Analysis
Attention to medication adherence and monitoring of HIV markers are critical to HIV 
care, but specialty clinics can be underfunded or located far from the patients who need 
the care. Thus while monitoring in HIV treatment can be effective, many patients do not 
have easy access to a clinic that provides monitoring. The ability of community 
pharmacists to provide monitoring and MTM and to increase adherence has been shown 
effective with other medical conditions, but most pharmacists are not doing so in a 
focused way for HIV. It is a logical step to bring a need for more monitoring together 
with an ability to monitor, and to engage more pharmacists in meeting this need.
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